A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs ALX 148 (Primary) ; Atezolizumab (Primary) ; Trastuzumab (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Alexo Therapeutics
- 10 Nov 2017 According to an Alexo Therapeutics media release, preliminary data were presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
- 24 Oct 2017 Planned number of patients changed from 110 to 142.
- 05 Oct 2017 According to an Alexo Therapeutics media release, data will be presented at the SITC 32nd Annual Meeting 2017.